Adverum Biotechnologies Completes Merger and Delisting

Adverum Biotechnologies ( (ADVM) ) has provided an announcement.

On December 9, 2025, Adverum Biotechnologies completed a merger, becoming a wholly owned subsidiary of its parent company. This led to significant changes in its corporate structure, including the resignation of its board of directors and the appointment of new directors and officers. Following the merger, Adverum Biotechnologies requested the suspension and delisting of its shares from the Nasdaq Stock Market and plans to terminate its registration and reporting obligations under the Securities Exchange Act.

The most recent analyst rating on (ADVM) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Adverum Biotechnologies stock, see the ADVM Stock Forecast page.

Spark’s Take on ADVM Stock

According to Spark, TipRanks’ AI Analyst, ADVM is a Neutral.

Adverum Biotechnologies’ overall stock score is primarily impacted by its challenging financial performance and valuation concerns. However, positive corporate events, including a merger with Eli Lilly and promising trial data, provide significant upside potential. Technical analysis indicates mixed signals, with some stability but also potential overbought conditions.

To see Spark’s full report on ADVM stock, click here.

More about Adverum Biotechnologies

Average Trading Volume: 726,634

Technical Sentiment Signal: Sell

Current Market Cap: $94.05M

For detailed information about ADVM stock, go to TipRanks’ Stock Analysis page.